Mineral Bone Disorders in Kidney Disease Patients: The Ever-Current Topic.
Hu L, Napoletano A, Provenzano M, Garofalo C, Bini C, Comai G, La Manna G.
Int J Mol Sci. 2022 Oct 13;23(20):12223. doi: 10.3390/ijms232012223.
PMID:36293076
Hypercalcemia: A Review.
Walker MD, Shane E.
JAMA. 2022 Oct 25;328(16):1624-1636. doi: 10.1001/jama.2022.18331.
PMID:36282253
Cancer-related hypercalcemia and potential treatments.
Almuradova E, Cicin I.
Front Endocrinol (Lausanne). 2023 Mar 22;14:1039490. doi: 10.3389/fendo.2023.1039490. eCollection 2023.
PMID:37033238
Vascular calcification: Molecular mechanisms and therapeutic interventions.
Pan W, Jie W, Huang H.
MedComm (2020). 2023 Jan 3;4(1):e200. doi: 10.1002/mco2.200. eCollection 2023 Feb.
PMID:36620697
Osteoporosis: Clinical Evaluation.
Lewiecki EM.
2024 Nov 2. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–.
PMID:25905277
Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease.
Miller PD, Adachi JD, Albergaria BH, Cheung AM, Chines AA, Gielen E, Langdahl BL, Miyauchi A, Oates M, Reid IR, Santiago NR, Vanderkelen M, Wang Z, Yu Z.
J Bone Miner Res. 2022 Aug;37(8):1437-1445. doi: 10.1002/jbmr.4563. Epub 2022 May 20.
PMID:35466448
Use of bisphosphonates in chronic kidney disease is associated with cardiovascular death.
Borghoff KA, Ounda AE, Swee ML, Girotra S, Shibli-Rahhal AA, Ten Eyck P, Jalal DI, Jovanovich AJ.